Hopwood Financial Services Inc. Purchases New Shares in Pfizer Inc. (NYSE:PFE)

Hopwood Financial Services Inc. purchased a new stake in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,125 shares of the biopharmaceutical company’s stock, valued at approximately $56,000.

A number of other institutional investors have also made changes to their positions in PFE. EverSource Wealth Advisors LLC increased its position in Pfizer by 1.4% in the fourth quarter. EverSource Wealth Advisors LLC now owns 35,435 shares of the biopharmaceutical company’s stock worth $940,000 after purchasing an additional 500 shares during the period. Summit X LLC increased its position in Pfizer by 15.6% in the fourth quarter. Summit X LLC now owns 14,756 shares of the biopharmaceutical company’s stock worth $392,000 after purchasing an additional 1,989 shares during the period. Natural Investments LLC acquired a new stake in Pfizer in the fourth quarter worth about $534,000. Donaldson Capital Management LLC increased its position in Pfizer by 1.2% in the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock worth $947,000 after purchasing an additional 410 shares during the period. Finally, Staley Capital Advisers Inc. increased its position in Pfizer by 3.5% in the fourth quarter. Staley Capital Advisers Inc. now owns 2,150,418 shares of the biopharmaceutical company’s stock worth $57,051,000 after purchasing an additional 73,594 shares during the period. 68.36% of the stock is owned by institutional investors.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of a number of research reports. Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Citigroup decreased their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Wednesday. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Price Performance

Shares of PFE opened at $25.73 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a 50 day simple moving average of $26.28 and a 200 day simple moving average of $27.18. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The firm has a market capitalization of $145.79 billion, a PE ratio of 18.24, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.10 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.